Cataract surgery - Toric and non toric implants Monofocal, premiumextended depth of focus (EDOF), diffractive, Trifocal Refractive lens exchange
SLT laser for raised pressure (selective laser Trabeculoplasty)
YAG capsulotomy for posterior capsule opacification (PCO) Laser iridotomy MIGS devices - OMNI, iStent, ELT, Preserflo, Xen
Professor Dan Lindfield – Consultant Ophthalmologist & Cataract and Glaucoma Surgeon
Professor Dan Lindfield is a multi-award-winning consultant ophthalmologist, widely recognized for his world-class expertise in cataract surgery and glaucoma treatment. Based in Guildford and Farnham, he serves as a consultant at Royal Surrey County Hospital and leads private practices at Farnham Eye Care and Spire Clare Park.
Expertise
Renowned for advanced cataract surgery, offering monofocal, toric, multifocal, EDOF, and AI-designed trifocal intraocular lens implants
Specialized in full-spectrum glaucoma care: SLT (Selective Laser Trabeculoplasty), trabeculectomy, tube shunt procedures, and Minimally Invasive Glaucoma Surgery (MIGS) including iStent, XEN, OMNI, Preserflo, ELT
Education & Professional Background
Earned his medical degree (BM) from the University of Southampton in 2004
Completed specialist ophthalmology training across Surrey, Sussex, Hampshire and London, including a glaucoma surgical fellowship at St Thomas' Hospital
Appointed Consultant Ophthalmologist in 2013 and elected Fellow of the Royal College of Ophthalmologists (FRCOphth) the same year
Holds the title of Honorary Visiting Professor of Ophthalmology at City St George’s, University of London, awarded in 2025
Practice & Private Care
NHS Consultant at Royal Surrey County Hospital, Guildford; also practices privately at Farnham Eye Care and Spire Clare Park Hospital
Farnham Eye Care is highly rated, offering locally accessible, world-class cataract and glaucoma services
Academic Contributions & Research
Published extensively, with over 33 peer-reviewed articles spanning cataract, glaucoma, MIGS, and other ophthalmic subspecialties
Guest editor for Journal of Glaucoma and peer reviewer for seven leading journals
Contributor to The Ophthalmologist as a writer, sharing advanced insights on MIGS and cataract safety
Recognition & Awards
Named one of the Top 50 “Rising Stars” in ophthalmology (Power List) in 2017
Ranked among the Top 100 Ophthalmologists in the world in 2018
Won a 2021 HSJ Patient Safety Award for pioneering a “drive-through” glaucoma clinic during the COVID-19 pandemic
Featured in Euro Health Leaders in 2024 as one of Europe’s most visionary leaders in eye care
Education & Training Leadership
Appointed Head of School for Ophthalmic Training across Kent, Surrey and Sussex in 2023
Concurrently serves as Training Programme Director at Health Education England, overseeing 33 trainee eye surgeons
BM Medicine, PGCert Med Ed, MRCOphth, FRCOphth.,
Glaucoma - SLT (Selective Laser Trabeculoplasty), MIGS devices (stents) including OMNI viscocanaloplasty, trabeculotomy, ELiOs ELT laser trabeculostomy, istent, Xen, Preserflo, trabeculectomy, tube shunt (Ahmed, Baerveldt, Paul).
YAG laser capsulotomy and iridotomy
English
New Patients £250.
Follow up £175 -Tests including optical biometry, OCT. (Visual fields may also be required)
SLT is a laser treatment used for open-angle glaucoma and ocular hypertension. It works by gently stimulating (or “tickling”) the cells in the trabecular meshwork (the eye’s drainage system) to improve aqueous humour outflow, which lowers intraocular pressure (IOP).
ALT (Argon Laser Trabeculoplasty) can damage the trabecular meshwork because it uses heat, leading to structural changes. Because of that, it carries a higher risk of side effects, and is now rarely used in the UK.
MLT (Micropulse Laser Trabeculoplasty) uses a laser that pulses on and off to reduce heat buildup. Its effectiveness and risks are similar to SLT, but whether it causes less inflammation is still under study.
It’s a safe and effective option that can reduce eye drops or delay their use.
After SLT, many patients can go 2 to 4 years without needing daily glaucoma medication, while achieving pressure reduction similar to one drop of medication.
It has quick recovery (often 1-2 days), is done as an outpatient procedure (no overnight stay), and takes only a few minutes per eye.
It reduces the need for more invasive eye surgery and may slow disease progression. There’s also evidence it might reduce the risk of cataract development.
Although generally very safe, SLT has potential mild side effects:
Mild redness or ache in the eye, which resolves in a few days.
Sensitivity to light (photophobia), also temporary.
A short-term increase in eye pressure in rare cases; prevented or treated with drops/tablets. The risk is very low (~1 in 800) with modern techniques.
Very rare complications such as iris adhesions, corneal or macular oedema have been reported but are very uncommon.
MIGS (Minimally Invasive Glaucoma Surgery) refers to a group of less invasive surgical procedures for glaucoma that aim to lower intraocular pressure (IOP) by improving the drainage of fluid inside the eye, or reducing its production. These approaches are generally safer, with faster recovery, fewer complications, and often preserve more of the eye’s natural anatomy. Glaucoma UK
MIGS is generally suitable for people with mild to moderate glaucoma. It’s commonly performed along with cataract surgery, since removing a cataract can itself help reduce IOP. The eye anatomy (especially the drainage angle) and disease stage are evaluated to assess whether MIGS is a good option. Glaucoma UK
It depends. For some people, MIGS reduces IOP enough that they can reduce or even stop some eye drops, at least for a while. But this effect may only last a few years, and some medications may still be needed. Importantly, MIGS doesn’t reverse any existing damage to the optic nerve; the goal is to prevent further damage.
Alternatives include:
Glaucoma medications (eye drops) Glaucoma UK
Laser treatments Glaucoma UK
More invasive glaucoma surgeries, such as trabeculectomy or aqueous shunt surgery Glaucoma UK
